Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372(9): 793-795.
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Vemurafenib – Benefit assessment according to § 35a Social Code Book V; Dossier assessment; commission A13-34. Cologne: IQWiG. 2013.
Ioannidis JP. Expectations, validity, and reality in omics. J Clin Epidemiol 2010; 63(9): 945-949.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6): 568-579.
Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics 2013; 14: 55.
Windeler J, Lange S. Nutzenbewertung personalisierter Interventionen: Methodische Herausforderungen und Lösungsansätze. Ethik Med 25: 173-182 (2013).
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.